{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T17:51:23Z","timestamp":1725558683256},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The role of basic fibroblast growth factor (bFGF) in chemoresistance is controversial; some studies showed a relationship between higher bFGF level and chemoresistance while other studies showed the opposite finding. The goal of the present study was to quantify bFGF levels in archived tumor tissues, and to determine its relationship with chemosensitivity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We established an image analysis-based method to quantify and convert the immunostaining intensity of intra-tumor bFGF to concentrations; this was accomplished by generating standard curves using human xenograft tumors as the renewable tissue source for simultaneous image analysis and ELISA. The relationships between bFGF concentrations and tumor chemosensitivity of patient tumors (n = 87) to paclitaxel were evaluated using linear regression analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The image analysis results were compared to our previous results obtained using a conventional, semi-quantitative visual scoring method. While both analyses indicated an inverse relationship between bFGF level and tumor sensitivity to paclitaxel, the image analysis method, by providing bFGF levels in individual tumors and therefore more data points (87 numerical values as opposed to four groups of staining intensities), further enabled the quantitative analysis of the relationship in subgroups of tumors with different pathobiological properties. The results show significant correlation between bFGF level and tumor sensitivity to the antiproliferation effect, but not the apoptotic effect, of paclitaxel. We further found stronger correlations of bFGF level and paclitaxel sensitivity in four tumor subgroups (high stage, positive p53 staining, negative aFGF staining, containing higher-than-median bFGF level), compared to all other groups. These findings suggest that the relationship between intra-tumoral bFGF level and paclitaxel sensitivity was context-dependent, which may explain the previous contradictory findings on the merit of using plasma or urine bFGF level as a prognostic indicator.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The present study established a quantitative image analysis method that enabled the measurement of intratumoral bFGF level in archived tissues. The ability to quantify a potential biomarker provided the opportunity to study the relationship between the biomarker and chemosensitivity in tumor subgroups and thereby enabled hypothesis generation for additional translational research.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1479-5876-6-4","type":"journal-article","created":{"date-parts":[[2008,1,18]],"date-time":"2008-01-18T19:13:14Z","timestamp":1200683594000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance"],"prefix":"10.1186","volume":"6","author":[{"given":"Colin T","family":"Walsh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Guillaume","family":"Wientjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie LS","family":"Au","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,18]]},"reference":[{"key":"234_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1046\/j.1365-2796.2003.01098.x","volume":"253","author":"P Nygren","year":"2003","unstructured":"Nygren P, Larsson R: Overview of the clinical efficacy of investigational anticancer drugs. J Intern Med. 2003, 253: 46-75. 10.1046\/j.1365-2796.2003.01098.x.","journal-title":"J Intern Med"},{"key":"234_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2165\/00003495-200363050-00005","volume":"63","author":"KF Croom","year":"2003","unstructured":"Croom KF, Perry CM: Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs. 2003, 63: 513-522. 10.2165\/00003495-200363050-00005.","journal-title":"Drugs"},{"key":"234_CR3","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005, 105: 2640-2653. 10.1182\/blood-2004-08-3097.","journal-title":"Blood"},{"issue":"Suppl 1","key":"234_CR4","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1093\/annonc\/12.suppl_1.S57","volume":"12","author":"W Eiermann","year":"2001","unstructured":"Eiermann W: Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol. 2001, 12 (Suppl 1): S57-S62. 10.1023\/A:1011172125897.","journal-title":"Ann Oncol"},{"key":"234_CR5","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2006.06.3958","volume":"24","author":"FR Hirsch","year":"2006","unstructured":"Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006, 24: 5034-5042. 10.1200\/JCO.2006.06.3958.","journal-title":"J Clin Oncol"},{"key":"234_CR6","first-page":"6145","volume":"61","author":"S Song","year":"2001","unstructured":"Song S, Wientjes MG, Walsh C, Au JL: Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res. 2001, 61: 6145-6150.","journal-title":"Cancer Res"},{"key":"234_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1368-7646(03)00023-2","volume":"6","author":"AB Coleman","year":"2003","unstructured":"Coleman AB: Positive and negative regulation of cellular sensitivity to anti-cancer drugs by FGF-2. Drug Resist Updat. 2003, 6: 85-94. 10.1016\/S1368-7646(03)00023-2.","journal-title":"Drug Resist Updat"},{"key":"234_CR8","first-page":"491","volume":"9","author":"A Huang","year":"1994","unstructured":"Huang A, Wright JA: Fibroblast growth factor mediated alterations in drug resistance, and evidence of gene amplification. Oncogene. 1994, 9: 491-499.","journal-title":"Oncogene"},{"key":"234_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1006\/excr.1994.1207","volume":"213","author":"A Huang","year":"1994","unstructured":"Huang A, Jin H, Wright JA: Aberrant expression of basic fibroblast growth factor in NIH-3T3 cells alters drug resistance and gene amplification potential. Exp Cell Res. 1994, 213: 335-339. 10.1006\/excr.1994.1207.","journal-title":"Exp Cell Res"},{"key":"234_CR10","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/bjc.1995.420","volume":"72","author":"T Ohta","year":"1995","unstructured":"Ohta T, Yamamoto M, Numata M, Iseki S, Tsukioka Y, Miyashita T, Kayahara M, Nagakawa T, Miyazaki I, Nishikawa K, Yoshitake Y: Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas. Br J Cancer. 1995, 72: 824-831.","journal-title":"Br J Cancer"},{"key":"234_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S0959-8049(96)00411-X","volume":"33","author":"M Volm","year":"1997","unstructured":"Volm M, Koomagi R, Mattern J, Stammler G: Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur J Cancer. 1997, 33: 691-693. 10.1016\/S0959-8049(96)00411-X.","journal-title":"Eur J Cancer"},{"key":"234_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1078\/0344-0338-00176","volume":"198","author":"A Faridi","year":"2002","unstructured":"Faridi A, Rudlowski C, Biesterfeld S, Schuh S, Rath W, Schroder W: Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer. Pathol Res Pract. 2002, 198: 1-5. 10.1078\/0344-0338-00176.","journal-title":"Pathol Res Pract"},{"key":"234_CR13","first-page":"2939","volume":"4","author":"VD Blanckaert","year":"1998","unstructured":"Blanckaert VD, Hebbar M, Louchez MM, Vilain MO, Schelling ME, Peyrat JP: Basic fibroblast growth factor receptors and their prognostic value in human breast cancer. Clin Cancer Res. 1998, 4: 2939-2947.","journal-title":"Clin Cancer Res"},{"key":"234_CR14","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/bjc.1997.536","volume":"76","author":"R Colomer","year":"1997","unstructured":"Colomer R, Aparicio J, Montero S, Guzman C, Larrodera L, Cortes-Funes H: Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer. 1997, 76: 1215-1220.","journal-title":"Br J Cancer"},{"key":"234_CR15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3816\/CBC.2003.n.039","volume":"4","author":"BK Linderholm","year":"2003","unstructured":"Linderholm BK, Lindh B, Beckman L, Erlanson M, Edin K, Travelin B, Bergh J, Grankvist K, Henriksson R: Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer. 2003, 4: 340-347.","journal-title":"Clin Breast Cancer"},{"key":"234_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1023\/A:1008303614441","volume":"10","author":"K Smith","year":"1999","unstructured":"Smith K, Fox SB, Whitehouse R, Taylor M, Greenall M, Clarke J, Harris AL: Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann Oncol. 1999, 10: 707-713. 10.1023\/A:1008303614441.","journal-title":"Ann Oncol"},{"key":"234_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/bjc.1997.5","volume":"75","author":"C Yiangou","year":"1997","unstructured":"Yiangou C, Gomm JJ, Coope RC, Law M, Luqmani YA, Shousha S, Coombes RC, Johnston CL: Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br J Cancer. 1997, 75: 28-33.","journal-title":"Br J Cancer"},{"key":"234_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0304-3835(98)00119-0","volume":"130","author":"A Obermair","year":"1998","unstructured":"Obermair A, Speiser P, Reisenberger K, Ullrich R, Czerwenka K, Kaider A, Zeillinger R, Miksche M: Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. Cancer Lett. 1998, 130: 69-76. 10.1016\/S0304-3835(98)00119-0.","journal-title":"Cancer Lett"},{"key":"234_CR19","first-page":"2157","volume":"3","author":"M Bredel","year":"1997","unstructured":"Bredel M, Pollack IF, Campbell JW, Hamilton RL: Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas. Clin Cancer Res. 1997, 3: 2157-2164.","journal-title":"Clin Cancer Res"},{"key":"234_CR20","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s11095-006-0136-6","volume":"23","author":"Y Gan","year":"2006","unstructured":"Gan Y, Wientjes MG, Au JL: Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res. 2006, 23: 1324-1331. 10.1007\/s11095-006-0136-6.","journal-title":"Pharm Res"},{"key":"234_CR21","first-page":"2086","volume":"56","author":"Y Gan","year":"1996","unstructured":"Gan Y, Wientjes MG, Schuller DE, Au JL: Pharmacodynamics of taxol in human head and neck tumors. Cancer Res. 1996, 56: 2086-2093.","journal-title":"Cancer Res"},{"key":"234_CR22","volume-title":"Statistical Methods","author":"George W Snedecor","year":"1980","unstructured":"Snedecor George, Cochran William: Statistical Methods. 1980, Ames, Iowa: The Iowa State University Press, 7","edition":"7"},{"key":"234_CR23","first-page":"4855","volume":"54","author":"MS Greenblatt","year":"1994","unstructured":"Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994, 54: 4855-4878.","journal-title":"Cancer Res"},{"key":"234_CR24","doi-asserted-by":"publisher","first-page":"8658","DOI":"10.1073\/pnas.140210697","volume":"97","author":"S Song","year":"2000","unstructured":"Song S, Wientjes MG, Gan Y, Au JL: Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA. 2000, 97: 8658-8663. 10.1073\/pnas.140210697.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-6-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:28:20Z","timestamp":1630463300000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-6-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,18]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["234"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-6-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,18]]},"assertion":[{"value":"19 September 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"4"}}